Marck Biosciences gets approval from South African drug authority
The drug firm has secures approval for six of its products.
Ahmedabad, January 4, 2013: The Ahmedabad-based Marck Biosciences has received approval from South African Medicines Control Council for six of its products manufactured at its Small Volume Parenterals (SVP) facility at Kheda, Gujarat. The sterile parenteral maker company said in a statement that the South African market is estimated at around US$ 3.8 billion and is growing at a pace of six per cent per annum. It is expected to reach US$ 7 billion in 2018, with generics accounting for 60 per cent of the volume.
The company also said that the approval will help in getting a quick access to markets like Namibia, Botswana, Zimbabwe, Swaziland, Lesotho, Zambia, Malawi and Madagascar, as South African Medicines Control Council (MCC) approval is expected to result in waiver of inspection by the authorities of these countries. It is worth mentioning here that MCC is a statutory body that oversees the regulation of medicines in South Africa.
The six products that received the approval from MCC-South Africa including Sterile Water for injections BP 5/10 ml; Ciprofloxacin Eye Drops 5/10 ml; Timolol 0.25 per cent Eye Drops 5/10 ml; Timolol 0. 50 per cent Eye Drops 5/10 ml; Lidocaine Injection BP 1 per cent 5/10 ml and Lidocaine Injection BP 2 per cent 5/10 ml.